Key facts
- PentaBind’s last known valuation is $8.5M (Jun 2025).
- It has raised $2.5M; the latest was Early Stage VC ($1.2M) in Jun 2025.
- Notable investors include Entrepreneurs First, London & Partners., Hoxton Ventures, Twin Path Ventures, BioIndustry Association — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for PentaBind
- ·The full record, as it builds
Funding rounds
No funding rounds for PentaBind are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PentaBind
Developer of precision aptamer therapeutics intended to treat unmet diseases. The company uses artificial intelligence and an integrated wet laboratory to design aptamers that can be used to detect and target almost any molecule of interest, enabling the biotechnology industry to develop new products and services for precision medicine, therapeutic design, and continuous monitoring.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- pentabind.com/
- Ownership
- Privately Held (backing)
PentaBind doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PentaBind shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PentaBind in its N-PORT filings yet. We sweep new filings monthly.